GLAXF News and Press, GlaxoSmithKline Plc From 01/14/21

Veeva is building the Industry Cloud for the global life sciences industry with solutions including a CRM suite, content and data management, and AI-powered data analytics. In Q3, Veeva reported a revenue growth rate of 34% y/y (acceleration) and a healthy gross margin of 72% (q/q imp...

The following slide deck was published by GlaxoSmithKline plc in conjunction with this event. For further details see: GlaxoSmithKline (GSK) Presents At Morgan Stanley ESG Conference 2020 - Slideshow

A 20-year back-testing study of my annual index for US-listed quality stocks reveals remarkably consistent outperformance on a risk-adjusted basis: Up to 21.1% in average annualized returns, 4.8% annualized alpha, average max drawdown of 8.8%, average Sortino ratio of 3.89, and an ave...

Ariel Investments’ 13F portfolio value increased from $6.57B to $6.89B this quarter. They increased Gilead Sciences while reducing ViacomCBS during the quarter. The top three positions are Baidu, Philip Morris, and Microsoft and they add up to ~15% of the portfolio. F...

Tweedy Browne’s 13F portfolio value increased from $2.51B to $2.58B this quarter. The largest five individual stock positions are Berkshire Hathaway, Alphabet, Johnson & Johnson, Cisco Systems, and Baidu, and they account for ~55% of the portfolio. Tweedy Browne increas...

Sanofi is working on a COVID-19 vaccine with GSK and planning to announce the outcome of 1/2 phase trials before the year ends. The company already has more than 600 million pre-orders for the vaccine. Robust demand for COVID-19 vaccines is likely to continue. To conclude, San...

Sanofi raised its 2020 EPS guidance for the second time this year, to 7-8% in CER terms. There are multiple medium-term drivers for earnings, including new products, sales growth for existing products and cost savings. Downside risks include growing generic competition and executi...

Silverback Therapeutics has filed proposed terms for its $125 million IPO. The firm is advancing programs to treat various highly prevalent forms of cancer. SBTX has produced initially intriguing results but investors will likely need to wait until 2022 to see a meaningful catalys...

Pfizer has been working on New Pfizer for almost a decade. The spin offs of Consumer Health and Upjohn appear to be the last steps. Continuation of the policy of dividend growth is a stated priority. Biopharma led by scientific pipeline innovation is expected to generate $15 ...

GlaxoSmithKline remains a high-yield pick in pharma, partially a consequence of several years of little growth and portfolio attrition to generics. Recent waves of drugs falling off-patent leave a substantial portfolio with a long while till patents expire. With three promising ap...